retina
(2)
Jason Ehrlich
Jason Ehrlich is the co-founder and CEO of Ollin Biosciences, an Austin-based clinical-stage biopharma launched in September 2025 with $100 million to build best-in-disease eye medicines. An MD-PhD ophthalmologist trained at Princeton and Stanford, he spent a decade at Genentech/Roche helping shepherd retina drugs including Lucentis and the bispecific faricimab (Vabysmo), then served five years as chief medical and development officer at Kodiak Sciences. At Ollin he is taking direct aim at the market leader: in early 2026 his lead asset OLN324 beat faricimab head-to-head in a randomized Phase 1b study, drying retinas faster and deeper with a clean safety record.
SamaCare
SamaCare is a San Francisco-based healthcare technology company that runs the leading medical-benefit prior authorization platform for specialty medications. Its cloud-based, AI-assisted software replaces the fax-and-phone paperwork that delays patients from receiving life-changing biologics, automating submission, tracking, benefit verification, and enrollment across major US payers. The platform serves specialty practices in retina, oncology, neurology, and rheumatology, plus pharmaceutical manufacturers who use SamaCare's real-time data to improve patient access.